LA Promulgated Several New Rules in Feb. and Mar. 2013

New Rules (13-04-429)
The Board completed the promulgation process for several new rules in February and March. More information about these new rules can be found on the Board’s Web site. The 2013 update for the Louisiana Pharmacy Law Book is scheduled for publication before the end of April.
♦ Regulatory Project 2012-5 ~ Institutional Pharmacies: Effective February 20
♦ Regulatory Project 2012-6 ~ Interstate Remote Process- ing: Effective February 20
♦ Regulatory Project 2012-7 ~ Security of Prescription Department: Effective February 20
♦ Regulatory Project 2012-8 ~ CDS License for Non- resident Distributor: Effective February 20
♦ Regulatory Project 2012-9 ~ CDS in Emergency Drug Kits: Effective February 20
♦ Regulatory Project 2012-10 ~ Prescription Monitoring Program: Effective February 20
♦ Regulatory Project 2012-11 ~ Durable Medical Equip- ment: Effective March 20 

quoted from source found here

Arkansas Compounding Pharmacy Inspections and Reminders

In response to the recent outbreak of fungal meningitis due to the inappropriate compounding of products, the Arkansas State Board of Pharmacy reminded licensees of its inspection requirements. The Board has completed regular inspections

of its pharmacies for years and it makes every effort to inspect each one at least once annually. The Board’s review of the 2012 inspections shows that 667 of the 748 pharmacies in Arkansas were inspected between January 1 and December 7. This number does not include additional site visits for changes of location, new openings, or the multiple visits and walk- throughs that the Board con- ducts routinely for its major compounding pharmacies. All of the Board’s pharmacy inspectors, as well as executive and assistant directors, are licensed pharmacists with experience and expertise in various areas of pharmacy practice. Board staff has sought out and received training in United States Pharmacopeia standards such as Chapter 797 and has incorporated sterile com- pounding inspection surveys into the Board’s workflow for any pharmacies that are preparing sterile products. While the Board does not claim this to be an absolute safety net, the Board continues to pursue additional opportunities for training and learning opportunities to continually improve it  efforts in inspecting com- pounding pharmacies.

The Board notes that any pharmacies that are prepar- ing compounded products for distribution in or into Arkansas, should review Regulation 07-02: COM- POUNDING, pertaining to pharmacy compounding, which details Board require- ments for sterility, potency, and endotoxin testing that must be followed prior to dispensing or administration of products.

Quoted from source found here

109th Annual NABP Meeting--Compounding/Manufacturing Debate: When Is a Duck Not A Duck?

May 18-21, 2013
Saturday, May 18, 2013
9 am - 7 pm
Registration/Information Desk Open
2 - 4 pm
Pre-Meeting CPE
The Compounding/Manufacturing Debate: When Is a Duck Not a Duck? ACPE #205-000-13-001-L03-P
(0.2 CEUs – 2 contact hours)
5 - 6 pm
Annual Meeting and District Meeting Orientation
7 - 10 pm
President’s Welcome Reception
Sponsored by Express Scripts Honoring NABP President Michael A. Burleson, RPh Dinner will be served
Dress: business casual
Sunday, May 19, 2013

Institute of Medicine Cites VAWD and VIPPS in Recommended Actions for Fighting Substandard Drugs in the US and Globally

Substandard and falsified medications have led
to thousands of cases of illness, injury, and death around the world, includ- ing the recent cases in the United States involving the distribution of a contaminated compounded inject- able drug to pain clinics and hospitals in 19 states, and the distribution of
fake cancer medication to numerous clinics around the country. Regulators tackling the problem – both in the US and abroad – face challenges including the complexity of the global pharmaceutical distribution chain and varied standards, regulations, and enforcement efforts.
continue to read here